Background: Ulcerative colitis (UC) is a chronic inflammatory bowel disease that is chronically present in patients throughout their lives. Hence, the chronic nature of the disease invariably requires continuous medical treatment. Advances in medical therapy over the last decades and current developments offer increasing options and are closely associated with a better life quality in patients. Summary: Recent developments in understanding the pathogenesis of UC are discussed. The current standard therapeutic regimens are outlined and recent developments and upcoming strategies introduced. Key Points: (1) Environmental factors that are yet to be defined contribute to the pathogenesis of UC. (2) An accelerated step-up therapy represents the current standard in UC. (3) Anti-integrins represent the most recently introduced pharmacological class in the therapy of UC. (4) Novel strategies including Janus kinase inhibitors are in the near future.

1.
Ellinghaus D, Jostins L, Spain SL, et al: Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016;48:510-518.
2.
Franke A, McGovern DP, Barrett JC, et al: Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet 2010;42:1118-1125.
3.
Molodecky NA, Soon IS, Rabi DM, et al: Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46-54.e42; quiz e30.
4.
Gensollen T, Iyer SS, Kasper DL, et al: How colonization by microbiota in early life shapes the immune system. Science 2016;352:539-544.
5.
Moayyedi P, Surette MG, Kim PT, et al: Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015;149:102-109.e6.
6.
Rossen NG, Fuentes S, van der Spek MJ, et al: Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 2015;149:110-118.e4.
7.
Dignass A, Lindsay JO, Sturm A, et al: Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030.
8.
Dignass A, Preiss JC, Aust DE, et al: [Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011]. Z Gastroenterol 2011;49:1276-1341.
9.
Marteau P, Probert CS, Lindgren S, et al: Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut 2005;54:960-965.
10.
Van Assche G, D'Haens G, Noman M, et al: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003;125:1025-1031.
11.
Laharie D, Bourreille A, Branche J, et al: Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012;380:1909-1915.
12.
Kruis W, Fric P, Pokrotnieks J, et al: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004;53:1617-1623.
13.
Panaccione R, Ghosh S, Middleton S, et al: Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014;146:392-400.e3.
14.
Carbonnel F, Colombel JF, Filippi J, et al: Methotrexate is not superior to placebo for inducing steroid-free remission, but induces steroid-free clinical remission in a larger proportion of patients with ulcerative colitis. Gastroenterology 2016;150:380-388.e4.
15.
Macaluso FS, Renna S, Cottone M, et al: The METEOR trial: the burial of methotrexate in ulcerative colitis? Gastroenterology 2016;151:211-212.
16.
Feagan BG, Rutgeerts P, Sands BE, et al: Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013;369:699-710.
17.
Sandborn WJ, Feagan BG, Rutgeerts P, et al: Vedolizumab as induction and maintenance therapy for Crohn's disease. N Engl J Med 2013;369:711-721.
18.
Danese S, Panés J: Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology 2014;147:981-989.
19.
Vermeire S, O'Byrne S, Keir M, et al: Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014;384:309-318.
20.
Sandborn WJ, Sands BE, D'Haens G, et al: Efficacy and safety of oral tofacitinib as induction therapy in patients with mo derate-to-severe ulcerative colitis: results from 2 phase 3 randomised controlled trials. J Crohns Colitis 2016;10/S1:OP019.
21.
Park W, Hrycaj P, Jeka S, et al: A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013;72:1605-1612.
22.
Yoo DH, Hrycaj P, Miranda P, et al: A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013;72:1613-1620.
23.
Farkas K, Rutka M, Golovics PA, et al: Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J Crohns Colitis 2016;10:1273-1278.
You do not currently have access to this content.